Small Cap Stock Laurus Labs Crosses Rs 1 Lakh Crore Market Cap: Are Valuations Justified? Buy, Hold Or Sell?

Laurus Labs has emerged as one of the biggest gainers in the pharmaceutical space, with the stock rally pushing the company’s market cap above Rs 1 lakh crore. The strong investor interest has been driven by a sharp recovery in earnings, improving margins and rising contribution from its Contract Development and Manufacturing Organisation (CDMO) business. However, the biggest question is if the stock is still attractive at current valuations or has the future growth already been priced in?

Strong Earnings Recovery Drives Stock Re-rating
Laurus Labs has seen a major turnaround after facing pressure due to weak pricing conditions in the API business and slower growth in previous years. The company has improved its business mix by focusing on higher-margin segments, particularly CDMO, which has helped profitability recover.

In FY26, the company reported revenue from operations of Rs 6,813 crore, registering a growth of 23% compared with the previous year. EBITDA increased 64% to Rs 1,826 crore, while EBITDA margin improved to 26.8% from 20.1% in FY25. Net profit also witnessed a sharp jump to Rs 889 crore.

CDMO Business Becomes The Key Growth Engine
The biggest reason behind Laurus Labs’ valuation expansion has been the strong performance of its CDMO business. This segment provides manufacturing support to global pharmaceutical companies and generally offers better margins compared with traditional generic businesses.

In FY26, CDMO revenue increased 36% to Rs 2,080 crore and contributed around 31% of the company’s overall revenue. The company is also expanding capabilities in areas such as biotechnology and advanced therapies, which could create additional growth opportunities over the long term. However, investors should remember that these businesses require continuous investment, strong execution and successful conversion of projects into commercial-scale manufacturing.

Valuation Is The Biggest Question Mark
While Laurus Labs has delivered strong operational improvement, the valuation remains a key factor for investors. With the market capitalisation crossing Rs 1 lakh crore, the stock is trading at a premium valuation compared with its historical levels. Such valuations are justified only when a company can consistently deliver strong earnings growth over several years.

The market is now expecting Laurus Labs to maintain high growth rates, expand its CDMO business further and protect margins. Any slowdown in growth, delay in capacity utilisation or pressure on profitability could impact the stock’s valuation. A good business can still become an expensive investment if expectations run ahead of fundamentals.

Growth Outlook Remains Positive But Execution Matters
The long-term opportunity for Laurus Labs remains attractive. Global pharmaceutical companies are increasingly outsourcing manufacturing, creating opportunities for Indian companies with strong technical capabilities and manufacturing infrastructure. The company’s focus on CDMO, expanding product pipeline and investments in advanced healthcare segments provide a strong foundation for future growth.

However, the next phase of growth will depend on execution. Investors will closely track new customer additions, commercialisation of projects, capacity utilisation and whether the recent margin improvement can be sustained.

Should Investors Buy, Hold Or Sell Laurus Labs?
For existing investors, Laurus Labs can be considered a Hold. The company’s business fundamentals have improved significantly, and the long-term growth opportunity remains intact. Investors who entered at lower levels may continue holding while monitoring earnings performance.

The key point for investors is that Laurus Labs is no longer a turnaround story; it is now a growth stock. The company must continue delivering strong earnings growth to justify the premium valuation.
 

About Laurus Labs
Laurus Labs Limited is a research-driven pharmaceutical company engaged in Active Pharmaceutical Ingredients (APIs), finished dosage formulations, CDMO services and biotechnology-related businesses. The company supplies pharmaceutical products to global markets and has developed capabilities across multiple segments of the healthcare value chain.
Also Read - Apple's India Top Line Gains on iPhone Duo, Threatened by Price-Driven Volume Drop

Disclaimer: The article is for informational purposes only and not investment advice.